CommercialPrior AuthMedium impact
Policy Criteria Change
Arkansas Blue Cross Blue Shield·AR · Oncology, Hematology·Medical Policy
Effective date
Jul 13, 2026
We identified it
Jun 19, 2026
Summary
Arkansas Blue Cross updated authorization renewal criteria for four oncology drugs: Mirvetuximab soravtansine-gynx (Elahere), Goserelin (Zoladex), Ramucirumab (Cyramza), and Daratumumab (Darzalex). Changes include new ECOG performance status requirements, expanded off-label indications for cancer treatment, and updated combination therapy criteria.
Action Required
Before July 13, 2026: Oncology billing team must review and update prior authorization renewal documentation requirements for Mirvetuximab soravtansine-gynx, Goserelin, Ramucirumab, and Daratumumab. Ensure clinical documentation includes ECOG performance status scores, treatment response evidence, and side effect management for renewals. Update provider templates to capture new off-label indication criteria for expanded cancer types.